MEDIPOST Co. Ltd (KQ:078160) — Market Cap & Net Worth

$93.28 Million USD  · ₩137.65 Billion KRW  · Rank #19531

Market Cap & Net Worth: MEDIPOST Co. Ltd (078160)

MEDIPOST Co. Ltd (KQ:078160) has a market capitalization of $93.28 Million (₩137.65 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19531 globally and #984 in its home market, demonstrating a 0.56% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying MEDIPOST Co. Ltd's stock price ₩8950.00 by its total outstanding shares 15379800 (15.38 Million). Also see MEDIPOST Co. Ltd total assets for a full breakdown of the balance sheet.

MEDIPOST Co. Ltd Market Cap History: 2015 to 2026

MEDIPOST Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $443.45 Million to $93.28 Million (-12.61% CAGR). Also see MEDIPOST Co. Ltd (078160) cash flow conversion for how efficiently the company converts equity into cash flow.

Index Memberships

MEDIPOST Co. Ltd is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
Kosdaq Composite Index
KOSDAQ
$234.31 Billion 0.04% #403 of 1384
Kosdaq Composite Index
KQ11
$234.31 Billion 0.04% #403 of 1384

Weight: MEDIPOST Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

MEDIPOST Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how MEDIPOST Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of MEDIPOST Co. Ltd for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

0.00x

MEDIPOST Co. Ltd's market cap is 0.00 times its annual revenue

Industry average: 0.11x Lower than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $443.45 Million $37.57 Billion $2.78 Billion 0.01x 0.16x
2016 $248.75 Million $28.65 Billion -$5.37 Billion 0.01x N/A
2017 $535.98 Million $42.25 Billion -$949.87 Million 0.01x N/A
2018 $335.33 Million $44.38 Billion -$2.01 Billion 0.01x N/A
2019 $320.67 Million $45.81 Billion -$14.12 Billion 0.01x N/A
2020 $317.01 Million $48.62 Billion -$1.90 Billion 0.01x N/A
2021 $196.07 Million $54.86 Billion -$683.26 Million 0.00x N/A
2022 $136.52 Million $64.20 Billion $3.07 Billion 0.00x 0.04x
2023 $85.05 Million $68.64 Billion $5.84 Billion 0.00x 0.01x
2024 $120.07 Million $70.66 Billion -$62.52 Billion 0.00x N/A

Competitor Companies of 078160 by Market Capitalization

Companies near MEDIPOST Co. Ltd in the global market cap rankings as of September 18, 2026. Review MEDIPOST Co. Ltd tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.

Key companies related to MEDIPOST Co. Ltd by market ranking:

  • Peptron Inc (KQ:087010): Ranked #7164 globally with a market cap of $1.54 Billion USD ( ₩2.27 Trillion KRW).
  • Bioneer Corporation (KQ:064550): Ranked #18070 globally with a market cap of $137.77 Million USD ( ₩203.30 Billion KRW).
  • Cell Biotech Co. Ltd (KQ:049960): Ranked #20139 globally with a market cap of $80.57 Million USD ( ₩118.89 Billion KRW).
  • Macrogen Inc (KQ:038290): Ranked #20177 globally with a market cap of $79.73 Million USD ( ₩117.65 Billion KRW).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#7164 Peptron Inc KQ:087010 $1.54 Billion ₩147900.00
#18070 Bioneer Corporation KQ:064550 $137.77 Million ₩9200.00
#20139 Cell Biotech Co. Ltd KQ:049960 $80.57 Million ₩15400.00
#20177 Macrogen Inc KQ:038290 $79.73 Million ₩11740.00

MEDIPOST Co. Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, MEDIPOST Co. Ltd's market cap moved from $443.45 Million to $ 93.28 Million, with a yearly change of -12.61%.

Year Market Cap Change (%)
2026 ₩93.28 Million -50.80%
2025 ₩189.59 Million +57.90%
2024 ₩120.07 Million +41.18%
2023 ₩85.05 Million -37.70%
2022 ₩136.52 Million -30.37%
2021 ₩196.07 Million -38.15%
2020 ₩317.01 Million -1.14%
2019 ₩320.67 Million -4.37%
2018 ₩335.33 Million -37.44%
2017 ₩535.98 Million +115.47%
2016 ₩248.75 Million -43.90%
2015 ₩443.45 Million --

End of Day Market Cap According to Different Sources

On Sep 18th, 2026 the market cap of MEDIPOST Co. Ltd was reported to be:

Source Market Cap
Yahoo Finance $93.28 Million USD
MoneyControl $93.28 Million USD
MarketWatch $93.28 Million USD
marketcap.company $93.28 Million USD
Reuters $93.28 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About MEDIPOST Co. Ltd

KQ:078160 Korea Biotechnology & Medical Research
Market Cap
$93.28 Million
₩137.65 Billion KRW
Market Cap Rank
#19531 Global
#984 in Korea
Share Price
₩8950.00
Change (1 day)
+3.23%
52-Week Range
₩7520.00 - ₩28000.00
All Time High
₩72522.12
About

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more